Nf-κbp65 and expression of its pro-inflammatory target genes are upregulated in the subcutaneous adipose tissue of cachectic cancer patients

Nutrients

Volumn 7, Issue 6, 2015, Pages 4465-4479

  Camargo, Rodolfo Gonzalez ^a   dos Reis Riccardi, Daniela Mendes ^a   Ribeiro, Henrique Quintas Teixeira ^a   Carnevali, Luiz Carlos ^a   de Matos Neto, Emidio Marques ^a   Enjiu, Lucas ^a   Neves, Rodrigo Xavier ^a   Lima, Joanna Darck Carola Correia ^a   Galvão Figuerêdo, Raquel ^a   de Alcântara, Paulo Sérgio Martins ^a   Maximiano, Linda ^a   Otoch, José ^a   Miguel Batista, Gerhard ^b   Püschel, Gerhard ^c   Seelaender, Marilia ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSIDADE DE MOGI DAS CRUZES   (Brazil)

^c UNIVERSITY OF POTSDAM   (Germany)

Author keywords

Cancer cachexia; Inflammation; I B; NF B; White adipose tissue

Indexed keywords

C REACTIVE PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NUCLEAR FACTOR KAPPA B P50; RIBOSOMAL PROTEIN L27; RIBOSOME PROTEIN; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CCL2 PROTEIN, HUMAN; I KAPPA B; I KAPPA B KINASE ALPHA; IFNG PROTEIN, HUMAN; IL1B PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; NFKBIA PROTEIN, HUMAN; RELA PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CACHEXIA; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LIPOLYSIS; MALE; OBSERVATIONAL STUDY; PROTEIN BINDING; PROTEIN EXPRESSION; QUALITY OF LIFE; QUESTIONNAIRE; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SUBCUTANEOUS FAT; UPREGULATION; WHITE ADIPOSE TISSUE; B LYMPHOCYTE; CASE CONTROL STUDY; GENETICS; METABOLISM; MIDDLE AGED; NEOPLASM; PATHOLOGY;

B-LYMPHOCYTES; CACHEXIA; CASE-CONTROL STUDIES; CHEMOKINE CCL2; FEMALE; HUMANS; I-KAPPA B PROTEINS; INTERFERON-GAMMA; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOLYSIS; MALE; MIDDLE AGED; NEOPLASMS; NF-KAPPAB INHIBITOR ALPHA; QUALITY OF LIFE; SIGNAL TRANSDUCTION; SUBCUTANEOUS FAT; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84930959839     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu7064465     Document Type: Article

References (39)

1. Fearon, K.C.; Moses, A.G. Cancer cachexia. Int. J. Cardiol. 2002, 85, 73–81.
2. Clay, W.D. Balancing the scales: A common-sense look at global nutrition problems and what can be done about them. World Rev. Nutr. Diet. 2008, 98, 179–197.
3. Barber, M.D.; Ross, J.A.; Fearon, K.C. Cancer cachexia. Surg. Oncol. 1999, 8, 133–141.
4. Lira, F.S.; Rosa, J.C.; Zanchi, N.E.; Yamashita, A.S.; Lopes, R.D.; Lopes, A.C.; Batista, M.L., Jr.; Seelaender, M. Regulation of inflammation in the adipose tissue in cancer cachexia: Effect of exercise. Cell Biochem. Funct. 2009, 27, 71–75.
5. Pajak, B.; Orzechowska, S.; Pijet, B.; Pijet, M.; Pogorzelska, A.; Gajkowska, B.; Orzechowski, A. Crossroads of cytokine signaling—The chase to stop muscle cachexia. J. Physiol. Pharmacol. 2008, 59 (Suppl. 9), 251–264.
6. Machado, A.P.; Costa Rosa, L.F.; Seelaender, M.C. Adipose tissue in Walker 256 tumour-induced cachexia: Possible association between decreased leptin concentration and mononuclear cell infiltration. Cell Tissue Res. 2004, 318, 503–514.
7. Batista, M.L., Jr.; Peres, S.B.; McDonald, M.E.; Alcantara, P.S.; Olivan, M.; Otoch, J.P.; Farmer, S.R.; Seelaender, M. Adipose tissue inflammation and cancer cachexia: Possible role of nuclear transcription factors. Cytokine 2012, 57, 9–16.
8. Booth, A.; Magnuson, A.; Fouts, J.; Foster, M. Adipose tissue, obesity and adipokines: Role in cancer promotion. Horm. Mol. Biol. Clin. Investig. 2015, 21, 57–74.
9. Trayhurn, P.; Wood, I.S. Adipokines: Inflammation and the pleiotropic role of white adipose tissue. Br. J. Nutr. 2004, 92, 347–355.
10. Arner, P. Medicine. Lipases in cachexia. Science 2011, 333, 163–164.
11. Barnes, P.J.; Karin, M. Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 1997, 336, 1066–1071.
12. Fraser, C.C. Exploring the positive and negative consequences of NF-kappaB inhibition for the treatment of human disease. Cell Cycle 2006, 5, 1160–1163.
13. Garg, A.; Aggarwal, B.B. Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia 2002, 16, 1053–1068.
14. Laurencikiene, J.; van Harmelen, V.; Arvidsson Nordstrom, E.; Dicker, A.; Blomqvist, L.; Naslund, E.; Langin, D.; Arner, P.; Ryden, M. NF-kappaB is important for TNF-alpha-induced lipolysis in human adipocytes. J. Lipid Res. 2007, 48, 1069–1077.
15. Saccani, A.; Schioppa, T.; Porta, C.; Biswas, S.K.; Nebuloni, M.; Vago, L.; Bottazzi, B.; Sica, A.; Colombo, M.P.; Mantovani, A. p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res. 2006, 66, 11432–11440.
16. Evans, W.J.; Morley, J.E.; Argiles, J.; Bales, C.; Baracos, V.; Guttridge, D.; Jatoi, A.; Lochs, H.; Kalantar-Zadeh, K.; Mantovani, G.; et al. Cachexia: A new definition. Clin. Nutr. 2008, 27, 793–799.
17. Aaronson, N.K.; Ahmedzai, S.; Bergman, B.; Bullinger, M.; Cull, A.; Duez, N.J.; Filiberti, A.; Flechtner, H.; Fleishman, S.B.; Haes, J.C.J.M.; et.al. The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology. J. Natl. Inst. 1986, 85, 365–376.
18. Pais-Ribeiro, J.; Pinto, C.; Santos, C. Validation studyof the portuguese version of the QLC-C30-V.3. Psicol. Saúde Doenças 2008, 9, 89–102.
19. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25, 402–408.
20. Richards, C.H.; Roxburgh, C.S.D.; McMillan, M.T.; Isswiasi, S.; Robertson, E.G.; Guthrie, G.K.; Horgan, P.G.; McMillan, D.C. The Relationships between Body Composition and the Systemic Inflammatory Response in Patients with Primary Operable Colorectal Cancer. PLoS ONE 2012, 7, e41883.
21. Fearon, K.; Strasser, F.; Anker, S.D.; Bosaeus, I.; Bruera, E.; Fainsinger, R.L.; Jatoi, A.; Loprinzi, C.; MacDonald, N.; Mantovani, G.; et al. Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 2011, 12, 489–495.
22. Argiles, J.M.; Moore-Carrasco, R.; Fuster, G.; Busquets, S.; Lopez-Soriano, F.J. Cancer cachexia: The molecular mechanisms. Int. J. Biochem. Cell Biol. 2003, 35, 405–409.
23. McMillan, D.C. Systemic inflammation, nutritional status and survival in patients with cancer. Curr. Opin. Clin. Nutr. Metab.Care 2009, 12, 223–226.
24. Gupta, S.C.; Kim, J.H.; Kannappan, R.; Reuter, S.; Dougherty, P.M.; Aggarwal, B.B. Role of nuclear factor kappaB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents. Exp. Biol. Med. 2011, 236, 658–671.
25. Deans, C.; Wigmore, S.J. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr. Opin. Clin. Nutr. Metab.Care 2005, 8, 265–269.
26. Sen, R.; Baltimore, D. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell 1986, 47, 921–928.
27. Schwartz, S.A.; Hernandez, A.; Mark Evers, B. The role of NF-kappaB/IkappaB proteins in cancer: Implications for novel treatment strategies. Surg. Oncol. 1999, 8, 143–153.
28. Rhoads, M.G.; Kandarian, S.C.; Pacelli, F.; Doglietto, G.B.; Bossola, M. Expression of NF-kappaB and IkappaB proteins in skeletal muscle of gastric cancer patients. Eur. J. Cancer 2010, 46, 191–197.
29. Op den Kamp, C.M.; Langen, R.C.; Snepvangers, F.J.; de Theije, C.C.; Schellekens, J.M.; Laugs, F.; Dingemans, A.M.; Schols, A.M. Nuclear transcription factor kappa B activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexia. Am. J. Clin. Nutr. 2013, 98, 738–748.
30. Cai, D.; Frantz, J.D.; Tawa, N.E., Jr.; Melendez, P.A.; Oh, B.C.; Lidov, H.G.; Hasselgren, P.O.; Frontera, W.R.; Lee, J.; Glass, D.J.; et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 2004, 119, 285–298.
31. Zhou, W.; Jiang, Z.W.; Tian, J.; Jiang, J.; Li, N.; Li, J.S. Role of NF-?B and cytokine in experimental cancer cachexia. World J. Gastroenterol. 2003, 9, 1567–1570.
32. Arner, P.; Langin, D. Lipolysis in lipid turnover, cancer cachexia, and obesity-induced insulin resistance. Trends Endocrinol. Metab. 2014, 25, 255–262.
33. Batista, M.L., Jr.; Olivan, M.; Alcantara, P.S.; Sandoval, R.; Peres, S.B.; Neves, R.X.; Silverio, R.; Maximiano, L.F.; Otoch, J.P.; Seelaender, M. Adipose tissue-derived factors as potential biomarkers in Cachectic cancer patients. Cytokine 2013, 61, 532–539.
34. Han, Y.; Meng, T.; Murray, N.R.; Fields, A.P.; Brasier, A.R. Interleukin-1-induced nuclear factor-kappaB-IkappaBalpha autoregulatory feedback loop in hepatocytes. A role for protein kinase calpha in post-transcriptional regulation of ikappabalpha resynthesis. J. Biol. Chem. 1999, 274, 939–947.
35. Argiles, J.M.; Busquets, S.; Lopez-Soriano, F.J. Anti-inflammatory therapies in cancer cachexia. Eur. J. Pharmacol. 2011, 668 (Suppl. 1), S81–S86.
36. Le Bail, O.; Schmidt-Ullrich, R.; Israel, A. Promoter analysis of the gene encoding the I kappa Balpha/ MAD3 inhibitor of NF-kappa B: Positive regulation by members of the rel/NF-kappa B family. EMBO J. 1993, 12, 5043–5049.
37. Narsale, A.A.; Enos, R.T.; Puppa, M.J.; Chatterjee, S.; Murphy, E.A.; Fayad, R.; Pena, M.O.; Durstine, J.L.; Carson, J.A. Liver Inflammation and Metabolic Signaling in ApcMin/+ Mice: The Role of Cachexia Progression. PLoS ONE 2015, 10, e0119888.
38. McClung, J.M.; Judge, A.R.; Powers, S.K.; Yan, Z. p38 MAPK links oxidative stress to autophagy-related gene expression in Cachectic muscle wasting. Am. J. Physiol. Cell Physiol. 2010, 298, C542–C549.
39. Moore-Carrasco, R.; Garcia-Martinez, C.; Busquets, S.; Ametller, E.; Barreiro, E.; Lopez-Soriano, F.J.; Argiles, J.M. The AP-1/CJUN signaling cascade is involved in muscle differentiation: Implications in muscle wasting during cancer cachexia. FEBS Lett. 2006, 580, 691–696.